The law has to catch up on orphan-designated drugs with multiple uses

A 340B rebate pilot collides with an ongoing problem for small pharmacies: when orphan-designated drugs have multiple uses.

340B藥品折扣項目的孤兒藥排除條款按藥品認定而非實際適應症執行，使藥房配發用於常見病的孤兒藥時反而虧損。作者主張HRSA在回扣試點的申報數據中加入診斷信息，並由國會修法把排除條件改為按實際用途判斷。